Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2017 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS)

Global Phase 3 Program Expected to Commence Before End of Q3 2017 International Phase 3 Trials Entitled “ULTIMATE I” and “ULTIMATE II” to be Led by Lawrence Steinman, MD, of Stanford University NEW...
June 26, 2017 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress

NEW YORK, June 26, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), recapped clinical data from two triple combination therapy trials using TGR-1202 (umbralisib), the Company’s oral,...
June 26, 2017 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology

MS patients treated with TG-1101 exhibited median B-cell depletion of 99% at week 4 TG-1101 was well tolerated with no grade 3/4 adverse events reported, with median time on study of 5 months ...
June 16, 2017 05:45 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma

GENUINE Phase 3 trial met its primary endpoint with TG-1101 (ublituximab) plus ibrutinib increasing Overall Response Rate (ORR) by >70% over ibrutinib alone in patients with high-risk CLL Triple...
June 15, 2017 04:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma

100% (4 of 4) ORR, including 50% CR rate in patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) 50% (6 of 12) ORR, including 42% CR rate in patients with chemo and/or SCT refractory DLBCL ...
June 14, 2017 12:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma

Combination of TGR-1202 (umbralisib) plus ibrutinib appears well tolerated with no Grade 3/4 transaminitis, pneumonitis, diarrhea, or colitis observed, with longest patients on study 29.5+ months 94%...
June 13, 2017 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress

NEW YORK, June 13, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today recapped the schedule of presentations featuring TG-1101 and TGR-1202 at the upcoming 14th International...
June 08, 2017 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma

NEW YORK, June 08, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the...
June 06, 2017 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Present at the 2017 Jefferies Global Healthcare Conference

NEW YORK, June 06, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at...
June 05, 2017 09:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology

100% ORR (19 of 19) observed in patients with CLL/SLL, including 32% CR rate 100% ORR (6 of 6) observed in patients with MZL and MCL, with 50% CR rate 80% ORR (4 of 5) observed in...